+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Supportive Care Drugs Market: By Drug Class, and By Cancer Type: Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 - 2025

  • ID: 5143594
  • Report
  • October 2019
  • Region: Global
  • 110 pages
  • Zion Market Research
The report covers forecast and analysis for the global cancer supportive care drugs market. The study provides historic data from 2016 to 2018 along with forecast from 2019 to 2025 based on revenue (USD Million). In-depth secondary research is used to ascertain overall market size, top industry players, top treatments, industry associations, etc. Macro-economic indicators such as healthcare industry outlook, healthcare spending, research funding, GDP along with company websites, company annual reports, white papers, financial reports and other sources have also been considered to arrive at the indicated market numbers.

Cancer treatment causes many side effects. Some of the side effects include pain, fatigue, loss of confidence and self-esteem, changes in sexuality, menopausal symptoms for women, fertility problems, lymphoedema, cognitive changes, depression, and other side effects. Some of these side effects are very serious medical conditions that needs to be treated and others are inconvenient or upsetting but are not harmful to health. Rise in such type of incidences in the disease and growing need to manage these effectively has led to the growth in the market for cancer supportive care drugs.

The study provides a decisive view on the cancer supportive care drugs market by segmenting the market based on product, cancer type, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on cancer type the market is segmented into granulocyte-colony stimulating factors (G-CSF), erythropoietin-stimulating agents (ESA), antiemetics, bisphosphonates, opioids, non-steroidal anti-inflammatory drugs (NSAID), and others. Granulocyte-colony stimulating factors and erythropoietin-stimulating agents are likely to grow at high CARG owing to the shift from biologics to biosimilars. The shift is backed by high mortality, patent loss, major safety issues associated with narcotic agents, and addiction.

Based on cancer type the market is segmented into breast cancer, lung cancer, melanoma, prostate cancer, and other cancers. Breast cancer segment is expected to grow at fastest rate in global market over the forecast period. Regional segmentation includes the current and forecast demand for Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries.

The study also includes drivers and restraints for the cancer supportive care drugs along with the impact they have on the demand over the forecast period. Besides, the report includes the study of opportunities and trends available in the cancer supportive care drugs market on global level. The market for cancer supportive drugs has a huge demand and is likely to grow in coming future. As per the stats provided by GLOBOCAN, 14.5 million new cancer cases were diagnosed worldwide in the year 2013. As per WHO, the growth in cancer cases is likely to raise by 75% in the next decade with more than 20 million new cancer cases. Cancer is highly dominant in middle and lower income countries due to lack of apt healthcare infrastructure to effectively combat this condition. Similarly, 65% of the total worldwide death related to cancer was reported from less developed regions.

The report also provides company market share analysis in order to give a broader view of the key players in the market. Industry insights and information is delivered in the required format. ZMR develops a list of industry players (manufacturers), distributors, retailers and industry experts. Some of the players included in cancer supportive care drugs market are Johnson & Johnson, Amgen, Merck, Heron Pharma, Roche, Helsinn Healthcare, and Tesaro.

The report segments the cancer supportive care drugs market as follows:

Global Cancer Supportive Care Drugs Market: Drug Class Segment Analysis
  • Granulocyte-Colony Stimulating Factors (G-CSF)
  • Erythropoietin-Stimulating Agents (ESA)
  • Antiemetic’s
  • Bisphosphonates
  • Opioids
  • Non-Steroidal Anti-Inflammatory Drugs (NSAID)
  • Others
Global Cancer Supportive Care Drugs Market: Cancer Type Segment Analysis
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Other Cancers
Global Cancer Supportive Care Drugs Market: Regional Segment Analysis
  • North America
  • U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
    • 2.2. Cancer Supportive Care Drugs Market: Snapshot
  • Chapter 3. Cancer Supportive Care Drugs Market - Industry Analysis
    • 3.1. Cancer Supportive Care Drugs Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government funding and support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Drug Class
      • 3.6.2. Market attractiveness analysis By Cancer Type
      • 3.6.3. Market attractiveness analysis by Region
  • Chapter 4. Cancer Supportive Care Drugs Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Cancer Supportive Care Drugs Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Drug Class launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Cancer Supportive Care Drugs Market -Drug Class Analysis
    • 5.1. Global Cancer Supportive Care Drugs Market overview: By Drug Class type
      • 5.1.1. Global Cancer Supportive Care Drugs Market share, By Drug Class,2018 and 2025
    • 5.2. Granulocyte-Colony Stimulating Factors (G-CSF)
      • 5.2.1. Global Cancer Supportive Care Drugs Market by Granulocyte-Colony Stimulating Factors (G-CSF), 2016-2025 (USD Million)
    • 5.3. Erythropoietin-Stimulating Agents (ESA)
      • 5.3.1. Global Cancer Supportive Care Drugs Market by Erythropoietin-Stimulating Agents (ESA), 2016-2025 (USD Million)
    • 5.4. Antiemetic's
      • 5.4.1. Global Cancer Supportive Care Drugs Market by Antiemetic's, 2016-2025 (USD Million)
    • 5.5. Bisphosphonates
      • 5.5.1. Global Cancer Supportive Care Drugs Market by Bisphosphonates, 2016-2025 (USD Million)
    • 5.6. Opioids
      • 5.6.1. Global Cancer Supportive Care Drugs Market by Opioids, 2016-2025 (USD Million)
    • 5.7. Non-Steroidal Anti-Inflammatory Drugs (NSAID)
      • 5.7.1. Global Cancer Supportive Care Drugs Market by Non-Steroidal Anti-Inflammatory Drugs (NSAID), 2016-2025 (USD Million)
    • 5.8. Others
      • 5.8.1. Global Cancer Supportive Care Drugs Market by others, 2016-2025 (USD Million)
  • Chapter 6. Global Cancer Supportive Care Drugs Market -Cancer Type Analysis
    • 6.1. Global Cancer Supportive Care Drugs Market overview: By Cancer Type
      • 6.1.1. Global Cancer Supportive Care Drugs Market share, By Cancer Type, 2018 and 2025
    • 6.2. Breast Cancer
      • 6.2.1. Global Cancer Supportive Care Drugs Market By Breast Cancer, 2016-2025 (USD Million)
    • 6.3. Lung Cancer
      • 6.3.1. Global Cancer Supportive Care Drugs Market By Lung Cancer, 2016-2025 (USD Million)
    • 6.4. Melanoma
      • 6.4.1. Global Cancer Supportive Care Drugs Market By Melanoma, 2016-2025 (USD Million)
    • 6.5. Prostate Cancer
      • 6.5.1. Global Cancer Supportive Care Drugs Market By Prostate Cancer, 2016-2025 (USD Million)
    • 6.6. Others
      • 6.6.1. Global Cancer Supportive Care Drugs Market by Other Cancer Types, 2016-2025 (USD Million)
  • Chapter 7. Global Cancer Supportive Care Drugs Market - Regional Analysis
    • 7.1. Global Cancer Supportive Care Drugs Market overview: by Region
      • 7.1.1. Global Cancer Supportive Care Drugs Market share, by Region, 2018 and 2025
    • 7.2. North America
      • 7.2.1. North America Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
      • 7.2.2. North America Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.2.3. North America Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.2.4. The U.S.
        • 7.2.4.1. The U.S.Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.2.4.2. The U.S.Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.2.5.2. Rest of North America Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
      • 7.3.2. Europe Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.3.3. Europe Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.3.4. UK
        • 7.3.4.1. U.K.Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.4.2. U.K.Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.5.2. France Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.3.6. Germany
        • 7.3.6.1. Germany Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.6.2. Germany Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.3.7. Rest of Europe
        • 7.3.7.1. Rest of EuropeCancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.3.7.2. Rest of EuropeCancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
      • 7.4.2. Asia Pacific Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.4.3. Asia Pacific Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.4.4. China
        • 7.4.4.1. China Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.4.2. China Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.4.5. Japan
        • 7.4.5.1. Japan Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.5.2. Japan Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.4.6. India
        • 7.4.6.1. India Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.6.2. India Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
      • 7.5.2. Latin America Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.5.3. Latin America Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.5.4.2. Brazil Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
      • 7.5.5. Rest of Latin America
        • 7.5.5.1. Rest of Latin America Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
        • 7.5.5.2. Rest of Latin America Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
      • 7.6.2. The Middle East and Africa Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
      • 7.6.3. The Middle East and Africa Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1. Johnson & Johnson
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Drug Class Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Amgen
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Drug Class Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Merck
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Drug Class Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Heron Pharma
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Drug Class Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. Roche
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Drug Class Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Helsinn Healthcare
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Drug Class Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Tesaro
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Drug Class Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. Company08
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Drug Class Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. Company09
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Drug Class Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
Note: Product cover images may vary from those shown
Adroll
adroll